As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
BUSINESS
Breyanzi Now Approved in Japan for 2nd-Line Large B-Cell Lymphoma: BMS
Bristol Myers Squibb said on December 20 that its CAR-T cell therapy Breyanzi (lisocabtagene maraleucel) has obtained a label expansion in Japan to allow its use for the second-line treatment of relapsed or refractory large B-cell lymphoma. The therapy is…
To read the full story
Related Article
- Yescarta, Breyanzi Clear Panel Review for Second-Line Use
December 13, 2022
BUSINESS
- Kyowa Kirin Debuts Crysvita Prefilled Syringe and Lumicef Auto-Injector in Japan
November 20, 2025
- Boehringer Sees Oncology as Pillar of Japan Business, Starting with Hernexeos
November 20, 2025
- Nxera to No Longer Invest in Non-Priority Assets, Shifts 80% of Pipeline to Obesity and Metabolic Areas
November 19, 2025
- Chugai to Absorb Renalys Pharma in Late December
November 19, 2025
- Nxera Unveils Restructuring Plan to Return to Profit, 15% Job Cuts in Japan and UK
November 18, 2025
Japan is set to tighten reimbursement rules for regenerative medicine products granted conditional, time-limited approval, with Central Social Insurance Medical…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…